Envista Holdings Corp (NVST) Stock Price & Analysis
Envista Holdings Corp (NVST) rose 0.61% to USD 26.33 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
NVST last closed at USD 26.17; the session ranged USD 26.16–26.77 on volume of 1,581,255 shares. Market capitalization is $4.28B, with a 52-week range of USD 18.77–30.42 (NYQ). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 26.33 |
|---|---|
| Change | ▲ 0.61% (up) |
| Previous Close | USD 26.17 |
| Open | USD 26.23 |
| Day Range | USD 26.16 – 26.77 |
| 52-Week Range | USD 18.77 – 30.42 |
| Volume | 1,581,255 shares |
| Market Cap | $4.28B |
| Exchange | NYQ |
Technical Analysis (NVST)
Nexqual's technical model rates NVST "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.89 (neutral) |
| vs SMA50 | Above (USD 25.08) |
| MACD | 0.29 (positive) |
Analyst Ratings (NVST)
Wall Street analysts rate NVST "Buy" based on 14 analysts, with a mean price target of USD 29.43 (range USD 21–35), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 29.43 |
| High Target | USD 35 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 7 / 9 / 0 |
Earnings (NVST)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.34 |
| Revenue Estimate | $716.48M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.36 vs est 0.31 ▲ beat |
| 2025-12-31 | USD 0.38 vs est 0.32 ▲ beat |
| 2025-09-30 | USD 0.32 vs est 0.28 ▲ beat |
| 2025-06-30 | USD 0.26 vs est 0.23 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (NVST)
| Total Revenue | $2.81B |
|---|---|
| Revenue Growth (YoY) | +14.40% |
| Gross Margin | +55.25% |
| Operating Margin | +9.87% |
| Profit Margin | +2.41% |
| ROE | +2.21% |
| Debt / Equity | 51.61 |
| Current Ratio | 2.44 |
| Total Cash | $1.08B |
| Total Debt | $1.59B |
| Free Cash Flow | $216.34M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (NVST)
Nexqual rates Envista Holdings Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 10% |
| Balance Sheet | Strong — $1.08B cash vs $1.59B debt |
| Cash Flow | Solid — FCF $216M, 8% margin |
| Efficiency | Weak — ROE 2%, ROA 3.0% |
Ownership (NVST)
| Insider Ownership | +0.48% |
|---|---|
| Institutional Ownership | +113.65% |
| Shares Outstanding | 162.73M |
| Float | 162.02M |
| Short % of Float | +6.77% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (NVST)
Envista Holdings Corp is led by Paul A. Keel (age 55), CEO & Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| CEO & Director | Paul A. Keel (age 55) |
|---|---|
| Senior VP & CFO | Eric D. Hammes (age 50) |
| Senior VP & President of Diagnostics | Robert Befidi (age 50) |
| Senior VP & President of Orthodontics | Veronica Acurio (age 54) |
| Vice President of Investor Relations | Jim Gustafson |
Major Backers & Investors (NVST)
Notable institutional backers of Envista Holdings Corp include Ariel Investments, LLC, Morgan Stanley, Franklin Resources, Inc., according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ariel Investments, LLC | 6.68% |
| Morgan Stanley | 5.4% |
| Franklin Resources, Inc. | 4.24% |
| Gates Capital Management, Inc. | 3.3% |
| Alliancebernstein L.P. | 3.09% |
| Ariel Investment Trust-Ariel Fund | 2.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.13% |
| BlackRock | 14.39% |
| Dimensional Fund Advisors | 6.01% |
| State Street | 3.21% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Envista Holdings Corp's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally.
- The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
- The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products.
- This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIVN | LivaNova PLC | USD 78.19 | ▼ 0.1% |
| EHC | Encompass Health Corporation | USD 112.89 | ▲ 1.68% |
| OPCH | Option Care Health, Inc. | USD 21.66 | ▲ 2.41% |
| ITGR | Integer Holdings Corporation | USD 98.62 | ▲ 2.13% |
| SHC | Sotera Health Company | USD 17.35 | ▲ 0.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.